Methods for treating and limiting fibrotic disorders and keloids

A technology for fibrotic diseases and scars, which is applied in the field of treatment and inhibition of fibrotic diseases and keloids, and can solve problems such as the lack of effective treatment methods for the disease

Inactive Publication Date: 2009-07-22
亚利桑那州董事会代表的亚利桑那州大学
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

There is currently no effective treatment for these diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating and limiting fibrotic disorders and keloids
  • Methods for treating and limiting fibrotic disorders and keloids
  • Methods for treating and limiting fibrotic disorders and keloids

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0112] Keloids and hypertrophic scars are abnormal healing disorders of fibrotic hyperplasia characterized by excessive scarring due to overproduction, deposition, and shrinkage of extracellular matrix, resulting in functional and cosmetic defects (Leask and Abraham, 2004 ). Currently there is no effective treatment for these diseases.

[0113] Transforming growth factor (TGF) β is one of the primary regulators that initiate the wound healing cascade. It mainly has three mammalian isoforms, namely TGF-β1, TGF-β2 and TGF-β3. TGF-β is a molecule with multiple functions, and its action depends on the cellular environment and the expression balance of each isoform. TGF-β1 is considered to be involved in initiating fibrotic responses, while TGF-β3 may have anti-fibrotic functions (Leask and Abraham, 2004, Miller and Nanchahal, 2005).

[0114] TGF-β promotes the expression of connective tissue growth factor (CTGF) in fibroblasts. CTGF is a cysteine-rich polypeptide that function...

Embodiment 2

[0144] Fibroblasts are widely recognized as a key cell type in fibrosis, wound healing and tissue repair. A small number of views also regard the transformation of fibroblasts into myofibroblasts as a key and possibly even necessary event for cells to perform the above functions (Powell et al., 1999 and Tomasek et al., 2002). Myofibroblasts are smooth muscle-like fibroblasts that express alpha-smooth muscle actin (α-SMA) and contain contractile structures composed of prominent stress fibers integrated with actin filaments and associated proteins (Tomasek et al. 2002). In addition to their normal role in maintaining tissue homeostasis and repair, alterations in the number and function of myofibroblasts have been associated with fibrotic diseases that result from increased deposition of extracellular matrix (ECM), such as those involving the lungs (pulmonary fibrosis), Diseases of blood vessels (intimal hyperplasia), heart (cardiac fibrosis), and skin (keloids) (Desmouliere et ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides methods for treating and/or limiting fibrotic disorders and/or treating or limiting scars selected from the group consisting of keloids and hypertrophic scars comprising administering to an individual in need thereof an amount effective to treat and/or limit scars selected from the group consisting of keloids and hypertrophic scars of a polypeptide comprising an HSP20- related polypeptide.

Description

[0001] related application [0002] The present application claims priority to U.S. Provisional Patent Application No. 60 / 830,279, filed July 12, 2006, and U.S. Provisional Patent Application No. 60 / 849,041, filed October 2, 2006, both of which are incorporated by reference All methods are incorporated in this article. [0003] Statement of Government Funding [0004] At least part of the work in this study was funded by NIH grant K25HL074968 and NIH STTR grant 6R42HL071309-03. The US Government has certain rights in this invention. Background technique [0005] Keloids and hypertrophic scars are a class of fibroproliferative abnormal healing disorders characterized by excessive scarring due to the overproduction, deposition, and shrinkage of extracellular matrix, resulting in functional and cosmetic defects (Leask and Abraham , 2004). Currently there is no effective treatment for these diseases. Contents of the invention [0006] In a first aspect, the present inventio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/00
Inventor 露茜安娜·比亚吉尼·洛佩斯伊丽莎白·J·弗尼士查尔斯·罗伯特·弗林帕米尼·科马拉维拉斯艾丽莎·帕尼什科林·M·布罗菲
Owner 亚利桑那州董事会代表的亚利桑那州大学
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap